Amendment: New insider Simcere Zaiming, Inc. claimed ownership of 338,636 shares (SEC Form 3)
$NXTC
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 06/20/2025 |
3. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) 08/19/2025 |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 338,636 | I | See footnotes(1)(2)(3)(4) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons"). |
| 2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote. |
| 3. The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| 4. This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form. |
| Remarks: |
| Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025 |
| Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer | 09/29/2025 | |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact | 09/29/2025 | |
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors | 09/29/2025 | |
| Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors | 09/29/2025 | |
| Jinsheng Ren By: /s/ Jinsheng Ren | 09/29/2025 | |
| Renhong Tang By: /s/ Renhong Tang | 09/29/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||